Peptide LibraryExenatide dosage in published studies and labels
These are the doses used for Exenatide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Exenatide has an FDA-approved human dosage. Byetta for adults with type 2 diabetes starts at 5 mcg twice daily under the skin within 60 minutes before the morning and evening meals, and can go to 10 mcg twice daily after 1 month. A once-weekly 2 mg extended-release form was compared with 10 mcg twice daily in the DURATION-1 trial; no Bydureon or Bydureon BCise label is listed on DailyMed as of this review.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous |
| Frequency | Twice daily before meals (Byetta); once weekly in extended-release trials |
| Duration studied | Continuous |
| Titration | Byetta: 5 mcg twice daily for 1 month, then 10 mcg twice daily based on response. |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Byetta, type 2 diabetesFDA-approved label · FDA prescribing information | Adults with type 2 diabetes mellitus | Start 5 mcg; 10 mcg after 1 month based on response | Subcutaneous, thigh, abdomen or upper arm | Twice daily, within 60 minutes before the morning and evening meals (or the two main meals, about 6 hours or more apart); never after a meal | Continuous, with diet and exercise | Glycemic control | BYETTA (exenatide) injection — FDA prescribing information, DailyMed |
| DURATION-1 — randomised, open-label trial (Drucker et al., 2008)Clinical trial · Phase 3 randomised non-inferiority trial (NCT00308139) | Adults with type 2 diabetes, drug-naive or on oral agents (n=295) | 2 mg once weekly (long-acting release) versus 10 mcg twice daily | Subcutaneous | Once weekly versus twice daily | 30 weeks | HbA1c fell 1.9% with once weekly versus 1.5% with twice daily | Drucker DJ et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1). Lancet 2008 |
Where sources disagree
- The two forms use different units and schedules: Byetta is micrograms twice a day, the extended-release form 2 mg once a week. Figures from one do not transfer to the other.
- DailyMed lists Byetta (AstraZeneca) and a generic exenatide injection, but no Bydureon or Bydureon BCise label as of 2026-11-07. The once-weekly dose shown here comes from a trial, not a current US label.
- The Byetta label says not to use it with other exenatide-containing products, and lists drug-induced immune thrombocytopenia from exenatide as a contraindication.